TEST PARAMETERS INCLUDED ON THE FINAL REPORT:
Every formal First Trimester Dual Marker report is structured across core analytical, sonographic, and statistical parameters:

• Free Beta Human Chorionic Gonadotropin (Free β-hCG): Raw serum concentration reported in ng/mL or IU/L.
• Free β-hCG MoM (Multiple of the Median): Normalized value adjusted for exact gestational age, weight, ethnicity, and maternal factors.
• Pregnancy-Associated Plasma Protein-A (PAPP-A): Raw serum concentration reported in mIU/mL or IU/L.
• PAPP-A MoM (Multiple of the Median): Normalized value adjusted for gestational age and maternal demographics.
• Nuchal Translucency (NT) Sonographic Measurement: Subcutaneous fluid collection at the back of the fetal neck measured in millimeters (mm) and translated into an NT MoM value.
• Fetal Nasal Bone (NB) Status: Recorded as Present, Absent, or Hypoplastic on the ultrasound input.
• Age-Only Background Risk: Base statistical risk calculated solely from maternal age at estimated date of delivery (EDD).
• Calculated Risk for Trisomy 21 (Down Syndrome): Overall personalized risk ratio synthesizing biochemistry and NT/NB inputs (e.g., 1:2500).
• Calculated Risk for Trisomy 18 (Edwards Syndrome) & Trisomy 13 (Patau Syndrome): Overall personalized combined risk ratio.
• Pathologist & Genetic Screening Specialist Remarks: Clinical summary explaining risk categorization (Screen Negative vs. Screen Positive) and recommending next diagnostic or confirmatory steps.

Why does the Dual Marker Advance AutoDELFIA test report require a 24 to 36-hour turnaround window?

Delivering precise quantitative results for prenatal risk calculation involves multi-stage processing. This includes serum separation, setting up time-resolved immunofluorometric runs on the automated AutoDELFIA analyzer, calibrating standard fluorescence curves, converting raw values into Multiples of the Median (MoMs), entering patient and ultrasound variables into LifeCycle 7.0 software, computing statistical risks, and review by our pathology and genetic screening team.

What is the difference between a screening test and a diagnostic test during pregnancy?

A screening test (such as the Dual Marker test or NIPT) calculates the statistical likelihood or probability that a baby may have a chromosomal condition, without posing any physical risk to the pregnancy. A diagnostic test (such as CVS or Amniocentesis) examines actual fetal cells to provide a definitive "yes" or "no" diagnosis.

Why is this test strictly limited to the gestational window of 11.0 to 13.6 weeks?

The biochemical separation of markers (Free β-hCG and PAPP-A) between normal pregnancies and those affected by Trisomy 21 is widest during this specific gestational window (fetal CRL 45 mm to 84 mm). Performing the test earlier or later invalidates the mathematical risk calculation medians.

What is "AutoDELFIA," and why is it considered the gold standard for prenatal screening?

AutoDELFIA (Automated Dissociation-Enhanced Lanthanide Fluorescent Immunoassay) utilizes time-delayed fluorescence with Europium tracers. Because it measures fluorescence only after natural background light has decayed, it provides higher analytical sensitivity, precision, and reproducibility compared to standard ELISA or basic chemiluminescence assays.

What does "MoM" (Multiple of the Median) mean on my report?

Because hormone levels naturally fluctuate with each day of pregnancy and vary with maternal body weight, raw values cannot be compared directly. The raw result is divided by the population median value for a healthy pregnancy at that exact gestational day and weight, yielding a standardized Multiple of the Median (MoM). A MoM of 1.0 represents the exact population average.

What does a "Screen Positive" or "High Risk" result mean?

A "Screen Positive" result does not mean the baby has a chromosomal disorder; it means the statistical probability is higher than the established cut-off (e.g., 1 in 80 instead of 1 in 1000). It indicates that further diagnostic evaluation—such as genetic counseling, NIPT, or amniocentesis—is recommended.

What does a "Screen Negative" or "Low Risk" result mean?

A "Screen Negative" result means the probability of the baby having Down Syndrome, Edwards Syndrome, or Patau Syndrome is low. While it provides substantial reassurance, no screening test can guarantee a 100% absence of all birth defects.

Why must Nuchal Translucency (NT) ultrasound measurements be included with the blood test?

Combining maternal serum biochemistry (Free β-hCG + PAPP-A) with ultrasound measurements of Nuchal Translucency (NT) and Nasal Bone (NB) increases the detection rate for Down Syndrome to approximately 90–95%, with a low false-positive rate (5%), compared to blood tests alone (65–70%).

Can a low PAPP-A level indicate pregnancy risks other than chromosomal abnormalities?

Yes. An isolated, significantly low PAPP-A level (< 0.4 to 0.5 MoM) in the presence of normal chromosomes reflects early placental insufficiency, which can be associated with an increased risk of developing preeclampsia, fetal growth restriction (FGR), or preterm delivery later in pregnancy.

Do I need to fast before providing a blood sample for a Dual Marker test?

No. Fasting is entirely unnecessary. Routine meals and water intake do not affect circulating Free β-hCG or PAPP-A levels, allowing you to have your blood drawn at any convenient time during the 11.0 to 13.6-week window.

Can twin pregnancies be screened using the Dual Marker test?

Yes. The LifeCycle software includes validated mathematical algorithms for twin gestations. In twin pregnancies, ultrasound measurements (individual NT for each fetus) carry significant weight alongside combined serum biochemistry.

How does maternal age affect the calculated Down Syndrome risk?

The biological background risk for chromosomal non-disjunction rises with advancing maternal age. The LifeCycle software starts with the mother's age-based prior risk and then adjusts it up or down based on the biochemical markers and ultrasound measurements.

What is the role of Non-Invasive Prenatal Testing (NIPT) if my Dual Marker shows intermediate risk?

NIPT analyzes cell-free fetal DNA circulating in maternal blood, offering >99% detection for Down Syndrome with a false-positive rate under 0.1%. It serves as a non-invasive follow-up step for intermediate screening results (1:250 to 1:1000).

Can IVF conception or progesterone support alter Dual Marker results?

Yes. Pregnancies achieved via In Vitro Fertilization (IVF) or those using exogenous hormone support can exhibit altered baseline hormone medians. Specifying IVF conception and donor age on the requisition form allows the software to make appropriate mathematical adjustments.

What is Nuchal Translucency (NT), and what is considered normal?

Nuchal Translucency is the normal fluid-filled space beneath the skin behind the fetal neck visible on first-trimester ultrasound. An NT measurement under 2.5 mm (or below the 95th percentile for the baby's CRL) is generally considered normal.

Is this maternal blood collection procedure safe for the baby?

Yes, completely safe. It requires a routine, non-invasive venous blood draw (3 mL) from the mother's arm, carrying zero physical risk to the pregnancy or the developing fetus.

What is Edwards Syndrome (Trisomy 18) and Patau Syndrome (Trisomy 13)?

These are severe chromosomal conditions caused by an extra copy of chromosome 18 or chromosome 13, respectively. They are characterized by multiple structural anomalies and developmental delays. Both conditions typically show very low levels of both Free β-hCG and PAPP-A on the Dual Marker test.

What is the standard immediate medical approach if my Dual Marker test returns high risk?

A high-risk result indicates a clear next step. Your obstetrician or fetal medicine specialist will review the ultrasound images, discuss the findings with you, and offer options such as genetic counseling, NIPT, or confirmatory diagnostic testing via Chorionic Villus Sampling (CVS) or Amniocentesis.

How can our family securely access and download our final digital PDF report file?

As soon as the AutoDELFIA run and LifeCycle risk calculations are verified and signed off by our consultant pathology team, your secure digital report can be downloaded from www.drpatholab.in using your registered credentials.

Are my personal prenatal records, genetic profiles, and laboratory data kept private?

Absolute adherence to medical privacy standards, sample identity logging protocols, and encrypted data channels across our digital infrastructure guarantees that your entire diagnostic and prenatal profile remains strictly confidential and secure.